PD-1/PD-L1 Inhibitor 3 |
| Catalog No.GC16258 |
PD-1/PD-L1 Inhibitor 3, a macrocyclic peptide, is a potent and selective inhibitor of the PD-1/PD-L1 and CD80/PD-L1 interactions extracted from patent WO2014151634A1, compound No.1. PD-1/PD-L1 Inhibitor 3 interferes with PD-L1 binding to PD-1 and CD80 by binding to PD-L1, with IC50s of 5.60 nM and 7.04 nM, respectively. PD-1/PD-L1 Inhibitor 3 can be used for the research of various diseases, including cancer and infectious diseases.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 1629654-95-0
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
PD-1/PD-L1 Inhibitor 3 is a PD-1/PD-L1 interaction inhibitor.
The anti-PD-1 and anti-PD-L1 compounds have been found to show impressive antitumor effects in various malignancies, such as melanoma. The greatest clinical outcome in unselected patients has been observed in melanoma. The tumor expression of PD-L1 is suggested to be a suggestive, inadequate, and predictive of response to immune-checkpoint blockade.
In vitro: PD-1/PD-L1 inhibitor 3 has been identified to be a potent and selective small molecule inhibitor blocking the interaction of programmed cell death protein 1 (PD-1) with its ligand protein (PD-L1) and with CD80. PD-1/PD-L1 inhibitor 3 was also found to act as an immunomodulator. In addition, PD-1/PD-L1 Inhibitor 3 was found to have highly efficacious binding to PD-L1 and promote the increased functional activities of T cells. Therefore, PD-1/PD-L1 inhibitor 3 could be regarded as a promising therapeutic treatment of cancer and infectious diseases, such as hepatitis C [1].
In vivo: So far, there is no animal in vivo study reported for PD-1/PD-L1 Inhibitor 3.
Clinical trial: Up to now, PD-1/PD-L1 Inhibitor 3 is still in the preclinical development stage.
References:
[1] MILLER Michael Matthew, et al. Patent, Pub. No.:WO/2014/151634
Average Rating: 5 (Based on Reviews and 37 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *